Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 8/20 | 0.46 |
| ▸ | LTA4H | P09960 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | CCR5 | P51681 | 1/20 | 0.40 |
| ▸ | CNR1 | P21554 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 1/20 | 0.39 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16193062 | 0.91 | HRH3 (0.48) | HRH3LTA4HKMT2ACNR2CHEK1 | |
| SCHEMBL20037952 | 0.91 | HRH3 (0.48) | HRH3LTA4HKMT2ACNR2CHEK1 | |
| SCHEMBL18291538 | 0.86 | RAB9A (0.52) | HRH3LTA4HKMT2AACHE | |
| SCHEMBL20037827 | 0.83 | HRH3 (0.48) | HRH3LTA4HKMT2AACHE | |
| SCHEMBL13187503 | 0.82 | HRH3 (0.56) | HRH3 | |
| SCHEMBL20037962 | 0.82 | PDE1B (0.46) | HRH3LTA4HKMT2A | |
| SCHEMBL20255406 | 0.82 | DRD2 (0.45) | HRH3LTA4HKMT2A | |
| SCHEMBL20038564 | 0.82 | KMT2A (0.43) | HRH3LTA4HKMT2A | |
| SCHEMBL4591964 | 0.81 | HRH3 (0.59) | HRH3 | |
| SCHEMBL20037857 | 0.81 | L3MBTL1 (0.51) | HRH3LTA4HKMT2ACCR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180161329-A1 | PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | TEIJIN PHARMA LIMITED (JP) | 2018-06-14 | — | — | US | disclosed |
| EP-3305785-A1 | PYRIDO[3,4-d]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | Teijin Pharma Limited (JP) | 2018-04-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180161329-A1 | PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | CDK4, CDK6, CDK16 | HRH3 2304/4885LTA4H 3374/4885KMT2A 670/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.